COVID-19 Vaccines Under Development Not Guaranteed to Work, Warns Merck CEO
By HospiMedica International staff writers Posted on 16 Jul 2020 |
Image: COVID-19 Vaccines Under Development Not Guaranteed to Work, Warns Merck CEO (Photo courtesy of Merck)
COVID-19 vaccines that are currently under development are not guaranteed to work and those claiming that a vaccine would be ready before the year-end are doing a “grave disservice to the public,” according to Kenneth Frazier, Chief Executive of Merck (Kenilworth, NJ, USA).
In an interview published on a Harvard Business School website, Frazier said that the potential COVID-19 vaccines may lack the qualities required for rapid deployment among a large population. “If you’re going to use a vaccine on billions of people, you better know what that vaccine does,” he said.
Frazier’s comments came soon after a US official stated that drugmakers partnering with the US government were on track to begin actively manufacturing a COVID-19 vaccine by summer end. The Trump administration has rolled out Operation Warp Speed Program with a target to produce 300 million vaccine doses by the end of 2021. Merck plans to study potential vaccine and therapy candidates for COVID-19 but has not yet begun clinical trials for its vaccine.
Frazier warned that some previous vaccines “not only didn’t confer protection, but actually helped the virus invade the cell, because it was incomplete in terms of its immunogenic properties. So we have to be very careful.”
Related Links:
Merck
In an interview published on a Harvard Business School website, Frazier said that the potential COVID-19 vaccines may lack the qualities required for rapid deployment among a large population. “If you’re going to use a vaccine on billions of people, you better know what that vaccine does,” he said.
Frazier’s comments came soon after a US official stated that drugmakers partnering with the US government were on track to begin actively manufacturing a COVID-19 vaccine by summer end. The Trump administration has rolled out Operation Warp Speed Program with a target to produce 300 million vaccine doses by the end of 2021. Merck plans to study potential vaccine and therapy candidates for COVID-19 but has not yet begun clinical trials for its vaccine.
Frazier warned that some previous vaccines “not only didn’t confer protection, but actually helped the virus invade the cell, because it was incomplete in terms of its immunogenic properties. So we have to be very careful.”
Related Links:
Merck
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans